Joseph A. November is an Associate Professor in the Department of History at the University of South Carolina, affiliated with the McCausland College of Arts and Sciences. His research focuses on the history of biomedical computing, distributed computing, and the intersection of technology and medicine. He holds a Ph.D. from Princeton University (2006), an M.A. from the University of Chicago (2002), and a B.A. from Hamilton College (1997). His work includes the award-winning book Biomedical Computing: Digitizing Life in the United States (2012), which explores the co-development of biomedicine and computing technologies. Current projects include Revolutions@home , examining distributed computing in protein folding research, and a biography of computing pioneer Robert S. Ledley. He has received grants from the NSF, NIH, and the Charles Babbage Institute. Teaching interests span the history of science and technology, including courses on the history of medicine, digital humanities, and the role of games in historical education. He actively contributes to professional organizations like SHOT and the History of Science Society. Awards include the Computer History Museum Prize (2013) and the National Institutes of Health DeWitt Stetten Fellowship (2007-2008). His research bridges historical analysis with contemporary issues in technology and biomedical ethics.
University of Illinois Urbana-ChampaignUnited States
Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .
John Oakey is a Professor and Graduate Coordinator in the Department of Chemical and Biomedical Engineering at the University of Wyoming, with additional affiliations to the INBRE Program, Molecular and Cellular Life Sciences Program, and Materials Science and Engineering Program. Education Postdoctoral Fellow, Center for Engineering in Medicine, Massachusetts General Hospital & Harvard Medical School (2007–2010) Ph.D. Chemical Engineering, Colorado School of Mines (2003) M.S. Chemical Engineering, Colorado School of Mines (1999) B.S. Chemical Engineering, Penn State University (1997) Research Interests Oakey’s laboratory integrates fluid dynamics, colloidal science and materials science to understand how biological systems behave under flow, on surfaces and within complex 3-D geometries. A unifying theme is the use of microfabrication and microfluidics to create new diagnostic, prognostic and therapeutic platforms. Current thrusts include: Heterogeneous biomaterials: self-assembled particulate tissue scaffolds whose mechanical and transport properties can be temporally programmed. Inertial microfluidics: exploiting lift forces for membrane-free particle sorting, enrichment and diagnostics. Multi-temporal analysis by flow cytometry: development of closed-loop, high-throughput microfluidic cytometers for longitudinal single-cell studies. Publication Trends From 2025 back to 2010, Oakey’s articles reveal a consistent trajectory that marries fundamental physics (microtubule mechanics, inertial focusing) with translational applications (cell encapsulation, tissue scaffolds, drug delivery). Recent work (2023-2025) increasingly targets injectable granular hydrogels, single-cell therapeutic delivery and sustainable carbon-sequestering living materials, demonstrating an evolution from microscale transport phenomena to macroscopic biomedical and environmental impact. Scientific Awards No named awards are listed in the supplied text. Advising & Coordination Roles As Graduate Coordinator for the Department of Chemical and Biomedical Engineering, Professor Oakey oversees graduate program development and student mentoring. While no individual students are named, his role implies active supervision of M.S. and Ph.D. advisees in chemical and biomedical engineering. Laboratory & Teams The Oakey Research Group operates from the Energy and Environmental Research Building (EERB 435A) at the University of Wyoming. The lab enjoys R1-level research infrastructure and collaborates broadly with the Wyoming INBRE network, the Molecular and Cellular Life Sciences Program, and the Materials Science and Engineering Program.
State University of New York at BuffaloUnited States
Youngjae You is a Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy. His research focuses on Antibody-Drug Conjugates, Cancer Chemotherapy, Medicinal Chemistry, and Targeted Drug Delivery. He holds adjunct roles at the University of Oklahoma Health Sciences Center and has led numerous grants totaling over $10 million in funding. Key awards include the 2019 Professor of Empire Innovation title and multiple DoD/CDMRP grants. His work emphasizes prodrug design, photodynamic therapy, and combination therapies. Education : PhD in Pharmaceutical Chemistry, Chungnam National University (2001) MS in Pharmaceutical Chemistry, Chungnam National University (2000) BPharm, Chungnam National University (1994) Research Interests : Dr. You specializes in developing light-activatable prodrugs for targeted cancer therapies, including far-red/NIR light-activated delivery systems. His work integrates quantitative pharmacokinetic modeling, singlet oxygen dynamics, and receptor-targeted drug conjugation to enhance therapeutic efficacy while minimizing off-target effects. Key applications include bladder, breast, and ovarian cancers. Funding Highlights : NIH/NIGMS: $1.37M (2023-2027) for light-responsive drug delivery National Cancer Institute: $2.1M (2022-2027) for bladder cancer treatments DoD/CDMRP/PRCRP: $392K (2017-2020) for photodynamic-chemotherapy combinations Awards : PHF Presidential Professorship (2018) American Cancer Society Research Scholar Grant (2013) Multiple DoD/CDMRP Idea Awards Service & Grants : Serves as Principal Investigator on 8 major grants. Active reviewer for Wellcome Trust, NIH, and international funding agencies. Holds patents on BODIPY derivatives and singlet oxygen-labile linkers. Lab & Collaborations : Leads the You Lab at UB, collaborating with bioengineers and clinicians to advance photomedicine and targeted drug delivery systems. Engaged in multidisciplinary teams addressing spatiotemporal control in cancer treatments.
Massachusetts Institute of TechnologyUnited States
Bradley Olsen is a Professor of Chemical Engineering at the Massachusetts Institute of Technology (MIT), holding the Alexander and I. Michael (1960) Kasser Chair in Chemical Engineering. He is affiliated with MIT's School of Engineering and directs research in the Plastics and the Environment Program. His academic career spans over two decades with numerous prestigious appointments and recognitions. Olsen earned his S.B. from MIT in 2003 followed by a Ph.D. from the University of California Berkeley in 2007. His educational background is complemented by postdoctoral fellowships including NIH and Beckman Institute Postdoctoral Fellowships (2008-2009) and the Hertz Fellowship (2003-2007). Research Interests Professor Olsen's research focuses on designing materials to address important challenges while understanding the fundamental science necessary for materials design. His primary research areas include block copolymers, soft condensed matter physics, protein-based materials, and bioelectronics. His group specializes in polymer networks, protein-polymer conjugates, self-assembly phenomena, and sustainable polymer development. The research has significant implications for biomaterials, sustainable polymers, and advanced materials design. Publication Trends Analysis of Professor Olsen's recent publications reveals a strong focus on polymer network topology, protein-polymer conjugates, and sustainable materials. His work increasingly integrates computational methods with experimental approaches, particularly in polymer characterization and data science applications to materials science. Recent publications show growing emphasis on biodegradable polymers, polymer informatics, and biomedical applications of advanced materials. Scientific Recognition Professor Olsen has received numerous prestigious awards throughout his career, including: American Physical Society (APS) Fellow (2023) Fulbright Amazonia Scholar (2023) Alexander and I. Michael Kasser Chair in Chemical Engineering (2021) ACS Macro Letters/Biomacromolecules/Macromolecules Young Investigator Award (2021) AIChE Owens Corning Early Career Award (2019) American Physical Society Dillon Medal (2018) Alfred P. Sloan Research Fellow in Chemistry (2014) Advising and Funding Professor Olsen has secured significant research funding from multiple federal agencies including NSF, NIH, AFOSR, and DOE. His group has produced numerous high-impact publications across top journals in polymer science, materials science, and chemistry. He has advised multiple graduate students and postdoctoral researchers who have gone on to successful careers in academia and industry. The MIT OGE's Committed to Caring Honor (2019) recognizes his excellence in graduate student mentoring. Research Infrastructure Professor Olsen leads a research group with capabilities spanning polymer synthesis, protein engineering, materials characterization, and computational modeling. His lab maintains strong collaborations with other MIT departments, national laboratories, and international research institutions. The group participates in several interdisciplinary initiatives including the Plastics and the Environment Program and has developed significant data infrastructure for polymer science through projects like CRIPT and BigSMARTS.
Roles & Affiliations: Ikhlas Khan serves as Director of the National Center for Natural Products Research (NCNPR), Distinguished Professor, and Research Professor of Pharmacognosy at the University of Mississippi's School of Pharmacy. He also leads the FDA Program and coordinates natural products research across multiple initiatives, including the Sino-US TCM Research Center and the Center for Research of Indian Systems of Medicine (CRISM). Education: B.Sc. Chemistry (1980) - Aligarh Muslim University, India M.Sc. Organic Chemistry (1982) - Aligarh Muslim University, India Ph.D. Pharmacy (1987) - Ludwig-Maximilians-Universität, Munich Postdoctoral Studies - Swiss Federal Institute of Technology (ETH), Zurich Research Focus: Dr. Khan specializes in natural products research with emphasis on: Phytomedicine: Standardization of herbal products via analytical fingerprinting, pesticide/herbicide residue analysis, and bioanalytical quality control. Drug Discovery: Isolation of bioactive natural products, development of analytical methods for phytochemical characterization, and chiral separation techniques. Metabolism Studies: Role of metabolism in drug/natural product activity, particularly in aminoquinoline antimalarials. His work bridges academia, industry, and regulatory bodies, shaping policies for botanical supplements. Key Contributions: Over 850 peer-reviewed publications and leadership in high-impact projects like the FDA Center of Excellence. His lab pioneered methods to combat herbal product adulteration and safety issues. Awards & Recognition: UM Distinguished Professor Award (2018) Wiley Award (AOAC International, 2018) Qihuang International Prize (2017) Honoris Causa Doctorate (University of Hamdard, 2012) Labs & Collaborations: Directs the NCNPR, a global leader in natural products research, and collaborates with institutions worldwide. His team develops technologies for herbal product authentication and drug metabolism studies.
Hai-Quan Mao is a Professor of Materials Science and Engineering at Johns Hopkins University, with a joint appointment in the Biomedical Engineering Department (School of Medicine). He directs the Institute for NanoBioTechnology (INBT) and leads the Translational Tissue Engineering Center. His research focuses on biomaterials, regenerative engineering, and immunoengineering, particularly developing nanomaterials for therapeutic delivery and tissue regeneration. Mao holds 35 U.S. patents, co-founded two biotech companies, and received prestigious awards including National Academy of Inventors Fellow and NSF CAREER Award. Education: BS in Chemistry (1988) and PhD in Polymer Chemistry (1993) from Wuhan University. Postdoctoral training at Johns Hopkins (1995–1998), followed by roles at Johns Hopkins Singapore (1999–2003) before joining the Whiting School faculty. Research emphasizes nanofiber scaffolds for liver/nerve regeneration, DNA/lipid nanoparticle engineering for gene therapy, and artificial lymph node matrices for immunotherapy. His lab translates biomaterials innovations into clinical applications, with NIH-funded projects addressing cancer, malaria, and tissue damage. Awards include over 60 provisional patents, multiple Johns Hopkins translational awards, and Thalheimer Awards for research. He serves as associate editor of Biomaterials and editorial board member of major journals. Lab activities include scalable nanoparticle manufacturing, machine learning for material design, and collaborations with industry/clinical partners. Recent work includes lipid nanoparticle optimization for mRNA vaccines and exosome-based therapies for Crohn’s disease.
University of North Carolina at Chapel HillUnited States
Gary Pielak is a Kenan Distinguished Professor of Chemistry, Biochemistry, and Biophysics at the University of North Carolina at Chapel Hill, with a joint appointment in the School of Medicine. His research focuses on high-resolution protein NMR studies in living cells and the biophysics of tardigrade desiccation-tolerance proteins, bridging structural biology and molecular biophysics. Education: BS in Chemistry from Bradley University (1977), PhD in Biochemistry from Washington State University (1983), Postdoc at the University of British Columbia (1983-1986), Postdoc at Oxford University (1986-1988). Research Interests center on understanding protein structure, stability, and function in physiologically relevant environments. Key areas include: In-Cell NMR: Quantifying protein behavior in living cells using advanced NMR techniques. Macromolecular Crowding: Studying synthetic polymers and proteins as crowding agents to mimic cellular environments. Tardigrade Biology: Exploring desiccation-tolerance mechanisms in intrinsically disordered proteins from water bears. Recent Publications highlight interdisciplinary trends, combining AI-driven stability prediction, solid-state NMR for dry protein analysis, and molecular glass/gel applications for preservation. His Scientific Awards include: NIH Pioneer Award DuPont and Morrow Young Faculty Awards Multiple UNC Mentorship Awards Mentorship is a cornerstone, with a focus on training graduate students and advancing NMR methodologies. His group employs Research Methods : 19F, 1H, 15N, and 13C NMR Circular Dichroism and Calorimetry Protein Expression in E. coli
Mayo Clinic College of Medicine and ScienceUnited States
Mark R. Pittelkow is a Professor of Dermatology at the Mayo Clinic, holding a primary appointment as a Consultant in the Department of Dermatology. He completed his MD at Mayo Medical School and advanced training through Mayo Graduate School of Medicine and Northwestern University. His research focuses on cutaneous lymphomas, photoprotection, and skin cancer, with leadership roles in international guidelines (ISCL/EORTC). He contributes to clinical trials, medical education, and interdisciplinary research through affiliations like the Mayo Clinic Comprehensive Cancer Center and Regenerative Biotherapeutics. Education: MD (Mayo Medical School), MS (Biological Sciences, Northwestern), BA (Northwestern University). Research spans cutaneous lymphoma classification, immunology, and translational dermatology. Notable publications address staging systems for mycosis fungoides/Sezary syndrome and photoprotection strategies. His work integrates clinical practice with molecular mechanisms, such as JAK inhibitor responses in lichen planus. Labs/Teams: Collaborates with Mayo Clinic Cancer Center and interdisciplinary groups in immunotherapy and regenerative medicine. Supervises clinical trials and postdoctoral training programs.
Michael McAlpine is a Professor in the Mechanical Engineering department at the University of Minnesota . He also holds affiliations with the Biomedical Engineering and Electrical and Computer Engineering departments. His research focuses on 3D printing functional materials & devices , Nanoscale inks , Biomedical devices , Bioelectronics , and Flexible Microsystems . Research Interests : 3D Printing, Biomedical Engineering, Nanotechnology, Flexible Electronics, Microfluidics Labs : ME 361/363 Contact : mcalpine@umn.edu , (612) 626-3303, ME 117 Recent Research Trends include 3D Printed Biomedical Devices , Flexible Electronics , and Bioprinting Applications . His work spans from Spinal Organoid Formation to Programmable Drug Release Capsules . Scientific Award : Circulation Research 2020 Best Manuscript Award
David Erickson is the SC Thomas Sze Director and Sibley College Professor at Cornell University's Sibley School of Mechanical and Aerospace Engineering. He also holds a joint professorship in the Division of Nutritional Sciences. His research focuses on global health technologies, medical diagnostics, microfluidics, photonics, nanotechnology, and energy systems. He previously served as Associate Dean of Engineering for Research and Graduate Programs. Erickson leads the NIH-funded PORTENT Center for Point-of-Care Technologies in Global Health and has co-founded companies like Dimensional Energy and VitaScan to commercialize diagnostic and energy technologies. Education: B.Sc., Mechanical Engineering, University of Alberta (1999) M.A.Sc., Mechanical Engineering, University of Toronto (2001) Ph.D., Mechanical Engineering, University of Toronto (2004) Postdoctoral Scholar, Electrical Engineering, California Institute of Technology (2005) Research Interests: Erickson’s work spans global health diagnostics , nanobio applications , and clean energy innovation . He develops portable medical devices for low-resource settings, including smartphone-integrated diagnostic tools for malaria, iron deficiency, and cancer. His lab also pioneers photothermal reactors for CO2 conversion into sustainable fuels. Key areas include: Point-of-care testing for infectious diseases and nutritional deficiencies Nanofluidic and optofluidic technologies for biomolecular analysis Solar-driven energy systems for carbon-neutral fuels Awards: Presidential Early Career Award for Scientists and Engineers (2011) Fellowships from the Optical Society, ASME, and Canadian Academy of Engineering Carbon X-Prize Finalist (2019) for Dimensional Energy’s CO2-to-fuel technology Grants & Industry Collaboration: Erickson’s research is funded by NIH, NSF, ARPA-E, DOE, and USAID. His lab’s innovations have spun off start-ups addressing global health and energy challenges. Notable projects include: - Portable cancer diagnostics in sub-Saharan Africa using mobile phone-based systems - Solar-powered CO2 conversion reactors tested in Wyoming and Arizona Labs & Teams: The Erickson Lab collaborates with the Cornell Atkinson Center for Sustainability and the McGovern Center for Entrepreneurship. Key initiatives include the PORTENT Center and the Dimensional Energy CO2-to-fuel project.
Massachusetts Institute of TechnologyUnited States
Connor Coley is the Henri Slezynger (1957) Career Development Assistant Professor at the Massachusetts Institute of Technology (MIT) School of Engineering. His research bridges chemistry and machine learning, focusing on autonomous molecular discovery, predictive chemistry, and laboratory automation. Education: Ph.D., MIT (2019) M.S.CEP., MIT (2016) B.S., Caltech (2014) Research Interests: Dr. Coley’s work centers on domain-informed machine learning for chemistry, computer-aided molecular design, and autonomous laboratories. Key themes include predictive modeling of chemical reactivity, optimization of synthesis pathways, and integration of AI with experimental data for drug discovery and materials science. Publications: His recent articles highlight advancements in AI-driven reaction prediction, molecular representation learning, and laboratory automation. Trends include applications of Bayesian optimization, contrastive learning, and diffusion models to chemical discovery. Scientific Awards: Camille Dreyfus Teacher-Scholar Award (2025) James W. Swan Outstanding Faculty (2025) Schmidt Futures AI2050 Early Career Fellow (2022) NSF CAREER Award (2021) Forbes 30 Under 30: Healthcare (2019) Software & Tools: He leads the open-source ASKCOS software suite for synthesis planning, adopted by 35,000+ chemists and deployed at 15+ pharmaceutical companies. His team also develops tools for metabolomics and molecular representation learning.
David H. Sherman is the Hans W. Vahlteich Professor of Medicinal Chemistry at the University of Michigan, holding joint appointments in the College of Pharmacy (Department of Medicinal Chemistry), Medical School (Microbiology & Immunology), and College of Literature, Science, and the Arts (Chemistry). He leads the Sherman Lab at the Life Sciences Institute and co-founded the Natural Products Discovery Core. His research focuses on natural product discovery, biosynthetic pathways, and drug development for infectious diseases, cancer, and neurological disorders. Education: PhD in Synthetic Organic Chemistry from Columbia University (1981), BA in Chemistry from UC Santa Cruz (1978). Postdoctoral research at MIT (1984). Research interests include microbial secondary metabolites, enzymatic catalysis (e.g., C-H functionalization, polyketide assembly), and high-throughput drug screening. He pioneered a microbial natural product library with over 50,000 samples. Current projects emphasize developing macrolide antibiotics and advancing compounds toward clinical trials through the Natural Products Biosciences Initiative. Collaborations span global institutions, with a focus on biodiversity conservation and capacity-building in low-income nations. He has mentored 67 PhD students, 60 postdocs, and 85+ undergraduates, fostering interdisciplinary training in chemical biology and microbial biochemistry. Labs/Teams: Sherman Lab (Life Sciences Institute), Center Member at Samuel and Jean Frankel Cardiovascular Center, Center for Computational Medicine and Bioinformatics, Rogel Cancer Center.
Andrew Spakowitz is a Professor of Chemical Engineering, Materials Science and Engineering, and by courtesy, Applied Physics and Chemistry at Stanford University. He currently serves as the Senior Associate Dean for Research and Faculty Affairs and holds the Tang Family Foundation Chair of the Department of Chemical Engineering. His academic career at Stanford spans from Assistant Professor (2006-2014) to Associate Professor (2014-2020) and now Professor since 2020. Dr. Spakowitz earned his PhD in 2004, MS in 2001 from the California Institute of Technology, and his BS in Chemical Engineering from the University of Wisconsin, Madison in 1999. He completed postdoctoral training in Molecular and Cell Biology and Biophysics at UC Berkeley from 2004-2006. His research focuses on theoretical and computational approaches to understanding biological processes and complex materials. The Spakowitz lab addresses fundamental chemical and physical phenomena through four main research themes: chromosomal organization and dynamics, protein self-assembly, polymer membranes, and charge transport in conducting polymers. His group employs diverse theoretical and computational methods including analytical theory of semiflexible polymers, polymer field theory, continuum elastic mechanics, Brownian dynamics simulation, equilibrium and dynamic Monte Carlo simulations, and reaction-diffusion modeling. Analysis of his recent publications reveals a strong emphasis on epigenetics and chromatin dynamics, with significant work on DNA methylation patterns, nucleosome clustering, and chromosome organization. His research also extends to polymer physics applications in biological systems, particularly in respiratory diseases, water purification membranes, and bacterial phage interactions with human mucus. Tang Family Foundation Chair of the Department of Chemical Engineering Professor Spakowitz mentors several graduate students and postdoctoral scholars in the Chemical Engineering and Materials Science departments. His lab members work on diverse projects spanning from chromatin dynamics to polymer membranes for water purification. He teaches multiple courses including CHEMENG 120B (Energy and Mass Transport), CHEMENG 340 (Molecular Thermodynamics), CHEMENG 466 (Polymer Physics), and CHEMENG 467 (Physics of Biomacromolecules). The Spakowitz lab operates from Clark S295 at Stanford University, conducting theoretical and computational research that bridges chemistry, physics, biology, and engineering disciplines to address complex problems across multiple length and time scales.
Weiping Tang is a Professor of Pharmaceutical Sciences and Chemistry at the University of Wisconsin-Madison, holding the Janis Apinis Professorship in the School of Pharmacy and the Vilas Distinguished Achievement Professorship. He also serves as Director of the Medicinal Chemistry Center at the School of Pharmacy and maintains a faculty appointment with the Department of Chemistry in the College of Letters and Science. Janis Apinis Professor of Pharmaceutical Sciences Vilas Distinguished Achievement Professor Director of Medicinal Chemistry Center Faculty Appointment with Department of Chemistry Dr. Tang received his B.S. in Chemistry from Peking University in 1997, M.S. in Chemistry from New York University in 1999, Ph.D. in Organic Chemistry from Stanford University in 2005, and completed a postdoctoral fellowship in Medicinal Chemistry, Chemical Biology and Drug Discovery at Harvard University in 2007. Dr. Tang's research program focuses on drug discovery for cancer, infectious diseases, and neurodegenerative disorders through three interconnected areas: Organic Synthesis (advancing glycoscience through novel carbohydrate synthesis technologies), Medicinal Chemistry (developing small molecules that selectively remove disease-associated proteins), and Chemical Biology (dissecting biological pathways using novel small molecule probes). His group operates as an interdisciplinary team where chemists and biologists collaborate closely on drug discovery projects, with particular emphasis on developing novel degraders for disease-causing proteins. Analysis of Dr. Tang's publication record reveals a significant shift toward targeted protein degradation technologies, particularly PROTACs and molecular glues, while maintaining strong foundations in carbohydrate chemistry. His most impactful recent work includes developing degraders for extracellular and membrane proteins (previously considered 'undruggable'), creating rapid synthesis platforms like Rapid-TAC and Rapid-Glue, and advancing understanding of ternary complex formation for novel PROTAC design. His research spans both chemical methodology development and therapeutic applications across multiple disease areas. Vilas Distinguished Achievement Professorship Janis Apinis Professorship Numerous high-impact publications in leading chemistry and pharmacology journals Editor's pick and hot paper designations for significant contributions Dr. Tang mentors a diverse team of graduate students, postdoctoral fellows, and staff scientists with expertise spanning synthetic chemistry, medicinal chemistry, carbohydrate chemistry, computational chemistry, biochemistry, and cell biology. His group has developed innovative platforms for the rapid synthesis of protein degraders and has made significant contributions to understanding the mechanisms of action for these novel therapeutics. Current research includes developing selective degraders for cancer targets like RIPK1, BRD4, and CARM1, as well as advancing delivery systems for clinical translation. The Tang Research Group maintains state-of-the-art facilities within the School of Pharmacy at UW-Madison, equipped for comprehensive chemical synthesis, compound characterization, and biological evaluation. The group actively collaborates with researchers across campus and with industry partners to advance discoveries toward clinical applications, with particular focus on cancer therapeutics and protein degradation technologies.
